CALQUENCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Calquence, and when can generic versions of Calquence launch?
Calquence is a drug marketed by Astrazeneca and is included in two NDAs. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and eighty-seven patent family members in fifty countries.
The generic ingredient in CALQUENCE is acalabrutinib maleate. One supplier is listed for this compound. Additional details are available on the acalabrutinib maleate profile page.
DrugPatentWatch® Generic Entry Outlook for Calquence
Calquence was eligible for patent challenges on October 31, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 1, 2036. This may change due to patent challenges or generic licensing.
There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALQUENCE?
- What are the global sales for CALQUENCE?
- What is Average Wholesale Price for CALQUENCE?
Summary for CALQUENCE
International Patents: | 187 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 54 |
Clinical Trials: | 44 |
Patent Applications: | 439 |
Drug Prices: | Drug price information for CALQUENCE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CALQUENCE |
What excipients (inactive ingredients) are in CALQUENCE? | CALQUENCE excipients list |
DailyMed Link: | CALQUENCE at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CALQUENCE
Generic Entry Dates for CALQUENCE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
Generic Entry Dates for CALQUENCE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for CALQUENCE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jeremy Abramson, MD | Phase 2 |
Ohio State University Comprehensive Cancer Center | Phase 2 |
Jonsson Comprehensive Cancer Center | Phase 1/Phase 2 |
Pharmacology for CALQUENCE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Tyrosine Kinase Inhibitors |
Paragraph IV (Patent) Challenges for CALQUENCE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CALQUENCE | Tablets | acalabrutinib maleate | 100 mg | 216387 | 1 | 2024-02-13 |
CALQUENCE | Capsules | acalabrutinib | 100 mg | 210259 | 5 | 2021-11-01 |
US Patents and Regulatory Information for CALQUENCE
CALQUENCE is protected by thirty-four US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CALQUENCE is ⤷ Try for Free.
This potential generic entry date is based on patent ⤷ Try for Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
EU/EMA Drug Approvals for CALQUENCE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AstraZeneca AB | Calquence | acalabrutinib | EMEA/H/C/005299 Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. |
Authorised | no | no | no | 2020-11-05 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CALQUENCE
When does loss-of-exclusivity occur for CALQUENCE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16286548
Patent: Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridiN-2-yl)benzamide
Estimated Expiration: ⤷ Try for Free
Patent: 20277123
Patent: Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Estimated Expiration: ⤷ Try for Free
Patent: 22291635
Patent: Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 91096
Patent: FORMES SOLIDES ET FORMULATIONS DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Chile
Patent: 17003445
Patent: Formas solidas y formulaciones de compuestos de imidazopirazina.
Estimated Expiration: ⤷ Try for Free
China
Patent: 8349978
Estimated Expiration: ⤷ Try for Free
Patent: 3480542
Patent: 化合物的固体形式和制剂 (Solid forms and formulations of compound)
Estimated Expiration: ⤷ Try for Free
Croatia
Patent: 0200934
Estimated Expiration: ⤷ Try for Free
Patent: 0211511
Estimated Expiration: ⤷ Try for Free
Patent: 0230417
Estimated Expiration: ⤷ Try for Free
Cyprus
Patent: 24519
Estimated Expiration: ⤷ Try for Free
Patent: 24815
Estimated Expiration: ⤷ Try for Free
Patent: 26103
Estimated Expiration: ⤷ Try for Free
Denmark
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 17281
Patent: FORMES SOLIDES ET FORMULATIONS DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Patent: FORMES ET FORMULATIONS SOLIDES DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Patent: FORMES ET FORMULATIONS SOLIDES DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 09493
Patent: FORMES SOLIDES ET FORMULATIONS DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A!PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Finland
Patent: 54690
Estimated Expiration: ⤷ Try for Free
Hong Kong
Patent: 50511
Estimated Expiration: ⤷ Try for Free
Hungary
Patent: 49989
Estimated Expiration: ⤷ Try for Free
Patent: 56008
Estimated Expiration: ⤷ Try for Free
Patent: 62258
Estimated Expiration: ⤷ Try for Free
Israel
Patent: 6633
Patent: צורות מוצקות ופורמולציות של (אס)-4-(8-אמינו-3-(1-(בוט-2-איינאויל)פירולידין-2-איל)אימידאזו[5,1-איי]פיראזין-1-איל)-אן-(פירידין-2-איל)בנזאמיד (Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide)
Estimated Expiration: ⤷ Try for Free
Patent: 4066
Patent: צורות מוצקות ופורמולציות של (אס)-4-(8-אמינו-3-(1-(בוט-2-איינאויל)פירולידין-2-איל)אימידאזו[5,1-איי]פיראזין-1-איל)-אן-(פירידין-2-איל)בנזאמיד (Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide)
Estimated Expiration: ⤷ Try for Free
Patent: 3821
Patent: צורות מוצקות ופורמולציות של (אס)-4-(8-אמינו-3-(1-(בוט-2-איינאויל)פירולידין-2-איל)אימידאזו[5,1-איי]פיראזין-1-איל)-אן-(פירידין-2-איל)בנזאמיד (Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide)
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 29215
Estimated Expiration: ⤷ Try for Free
Patent: 91494
Estimated Expiration: ⤷ Try for Free
Patent: 18522877
Patent: (S)−4−(8−アミノ−3−(1−(ブト−2−イノイル)ピロリジン−2−イル)イミダゾ[1,5−a]ピラジン−1−イル)−N−(ピリジン−2−イル)ベンザミドの固体形態及び製剤
Estimated Expiration: ⤷ Try for Free
Patent: 21073235
Patent: (S)−4−(8−アミノ−3−(1−(ブト−2−イノイル)ピロリジン−2−イル)イミダゾ[1,5−a]ピラジン−1−イル)−N−(ピリジン−2−イル)ベンザミドの固体形態及び製剤 (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 22120156
Patent: (S)-4-(8-アミノ-3-(1-(ブト-2-イノイル)ピロリジン-2-イル)イミダゾ[1,5-a]ピラジン-1-イル)-N-(ピリジン-2-イル)ベンザミドの固体形態及び製剤
Estimated Expiration: ⤷ Try for Free
Lithuania
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Estimated Expiration: ⤷ Try for Free
Malaysia
Patent: 3514
Patent: SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1, 5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 18000179
Patent: FORMAS SOLIDAS Y FORMULACIONES DE (S)-4-(8-AMINO-3-(1-(BUT-2-INOIL )PIRROLIDIN-2-IL)IMIDAZO[1,5-A]PIRAZIN-1-IL)-N-(PIRIDIN-2-IL)BENZ AMIDA. (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PY RIDIN-2-YL)BENZAMIDE.)
Estimated Expiration: ⤷ Try for Free
Patent: 20014163
Patent: FORMAS SOLIDAS Y FORMULACIONES DE (S)-4-(8-AMINO-3-(1-(BUT-2-INOIL )PIRROLIDIN-2-IL)IMIDAZO [1,5-A]PIRAZIN-1-IL)-N-(PIRIDIN-2-IL)BENZ AMIDA. (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PY RIDIN-2-YL)BENZAMIDE.)
Estimated Expiration: ⤷ Try for Free
Moldova, Republic of
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Morocco
Patent: 297
Patent: Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
Estimated Expiration: ⤷ Try for Free
Patent: 817
Patent: FORMES ET FORMULATIONS SOLIDES DE (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE
Estimated Expiration: ⤷ Try for Free
Patent: 556
Patent: Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
Estimated Expiration: ⤷ Try for Free
Poland
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Estimated Expiration: ⤷ Try for Free
Portugal
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Estimated Expiration: ⤷ Try for Free
Russian Federation
Patent: 18103913
Patent: ТВЕРДЫЕ ФОРМЫ И КОМПОЗИЦИИ (S)-4-(8-АМИНО-3-(1-(БУТ-2- ИНОИЛ)ПИРРОЛИДИН-2-ИЛ)ИМИДАЗО[1,5-A]ПИРАЗИН-1-ИЛ)-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
Estimated Expiration: ⤷ Try for Free
San Marino
Patent: 02000304
Estimated Expiration: ⤷ Try for Free
Patent: 02100597
Estimated Expiration: ⤷ Try for Free
Patent: 02300165
Estimated Expiration: ⤷ Try for Free
Serbia
Patent: 411
Patent: ČVRSTI OBLICI I FORMULACIJE (S)-4-(8-AMINO-3-(1-(BUT-2-INOIL)PIROLIDIN-2-IL)IMIDAZO[1,5-A]PIRAZIN-1-IL)-N-(PIRIDIN-2-IL)BENZAMIDA (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 455
Patent: ČVRSTI OBLICI I FORMULACIJE (S)-4-(8-AMINO-3-(1-(BUT-2-INOIL)PIROLIDIN-2-IL)IMIDAZO[1,5-A]PIRAZIN-1-IL)-N-(PIRIDIN-2-IL)BENZAMIDA (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Patent: 195
Patent: ČVRSTI OBLICI I FORMULACIJE (S)-4-(8-AMINO-3-(1-(BUT-2-INOIL)PIROLIDIN-2-IL)IMIDAZO[1,5-A]PIRAZIN-1-IL)-N-(PIRIDIN-2-IL)BENZAMIDA (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE)
Estimated Expiration: ⤷ Try for Free
Singapore
Patent: 201913796U
Patent: SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE
Estimated Expiration: ⤷ Try for Free
Slovenia
Patent: 17281
Estimated Expiration: ⤷ Try for Free
Patent: 13745
Estimated Expiration: ⤷ Try for Free
Patent: 54690
Estimated Expiration: ⤷ Try for Free
South Africa
Patent: 1800329
Patent: SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE
Estimated Expiration: ⤷ Try for Free
Patent: 2000300
Patent: SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE
Estimated Expiration: ⤷ Try for Free
South Korea
Patent: 2688052
Estimated Expiration: ⤷ Try for Free
Patent: 180048593
Estimated Expiration: ⤷ Try for Free
Patent: 240115937
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 97987
Estimated Expiration: ⤷ Try for Free
Patent: 95802
Estimated Expiration: ⤷ Try for Free
Patent: 46489
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering CALQUENCE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Serbia | 64195 | ⤷ Try for Free | |
Australia | 2004282219 | Imidazo '1, 5 - A | ⤷ Try for Free |
Hong Kong | 1250511 | (s)-4-(8-氨基-3-(1-(2-丁炔氨基)吡咯烷-2-基)-咪唑並[1,5-A]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺的固體形式和製劑 (SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1 -(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE) | ⤷ Try for Free |
Mexico | 2014000746 | ⤷ Try for Free | |
Morocco | 42297 | Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | ⤷ Try for Free |
New Zealand | 716110 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CALQUENCE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2734522 | 2021016 | Norway | ⤷ Try for Free | PRODUCT NAME: AKALABRUTINIB; REG. NO/DATE: EU/1/20/1479 20201111 |
2734522 | 2021C/512 | Belgium | ⤷ Try for Free | PRODUCT NAME: ACALABRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1479 20201106 |
2734522 | PA2021004 | Lithuania | ⤷ Try for Free | PRODUCT NAME: AKALABRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1479/001-EU/1/20/1479/002 20201105 |
2734522 | 2190009-7 | Sweden | ⤷ Try for Free | PRODUCT NAME: ACALABRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1479 20201106 |
2734522 | PA2021004,C2734522 | Lithuania | ⤷ Try for Free | PRODUCT NAME: AKALABRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/20/1479/001-EU/1/20/1479/002 20201105 |
2734522 | SPC/GB21/019 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: ACALABRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/20/1479 (NI) 20201106; UK PLGB 17901/0353 20201106 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for CALQUENCE
More… ↓